###begin article-title 0
###xml 40 44 40 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
Endothelial nitric oxide synthase gene T-786C and 27-bp repeat gene polymorphisms in retinopathy of prematurity
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 354 358 354 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 143 150 <span type="species:ncbi:9606">infants</span>
Retinopathy of prematurity (ROP), which is associated with abnormal retinal vessel development, is the leading cause of visual loss in preterm infants. Endothelial nitric oxide synthase (eNOS) is believed to play a central role in both retinal angiogenesis and vasculogenesis. The aim of this study was to investigate functional genetic polymorphisms of eNOS in the pathogenesis of ROP.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 6 10 6 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 173 180 <span type="species:ncbi:9606">infants</span>
###xml 265 272 <span type="species:ncbi:9606">infants</span>
eNOS T-786C and 27-bp repeat (eNOS, b: wild-type, a: mutant) genotypes were determined using allele-specific polymerase chain reaction in 105 low birth weight (LBW) preterm infants treated for ROP (treated group). A control group was set up and composed of 127 LBW infants with stage 1 or 2 ROP that did not not require treatment (untreated group).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 165 169 165 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 171 175 171 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 433 437 433 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
The genotype distribution of eNOS 27-bp repeat polymorphism was found to significantly differ (p=0.015) between the two groups, whereas the genotype distribution of eNOS T-786C did not differ (p=0.984) between the groups. There was no difference in the distribution of either the "a" allele (p=0.153) nor of the C allele (p=0.867) in a groups comparison. Multiple logistic regression analysis revealed that male gender (p=0.046) and eNOS aa genotype (p=0.047 versus ab genotype and p=0.022 versus bb genotype) were significantly associated severe ROP that required treatment. The haplotype estimations based on the detected genotype distributions showed that the prevalence of aT and bT haplotypes was significantly increased in the group treated for ROP.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 135 139 135 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 141 145 141 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
Functional eNOS 27-bp repeat polymorphism might be associated with the risk of severe ROP, however we found no association between the eNOS T-786C and the pathogenesis of ROP.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 75 76 75 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 555 556 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
Retinopathy of prematurity (ROP) is a major cause of blindness in infancy [1]. After preterm birth, the developing retina is exposed to a sudden increase in tissue oxygen tension resulting in the generation of reactive free radicals which may lead to impairment of retinal vascular development and even to loss of already developed retinal capillaries (ROP phase I). This insufficient vascularization results in retinal hypoxia, which, in turn, induces a release of various growth factors, stimulating new and abnormal blood vessel growth (ROP phase II) [2].
###end p 11
###begin p 12
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 408 409 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
Nitric oxide (NO) is a free radical molecule that plays an essential role in numerous physiological actions, including vasoregulation, inhibition of platelet aggregation, and immunological reactions [3]. Endothelial nitric oxide synthase (eNOS), an isoform of NO-producing enzymes that is fairly specific to endothelial cells, has been found to play a prominent role in both angiogenesis and vasculogenesis [4].
###end p 12
###begin p 13
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 402 403 402 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
NO triggers the gene expression and activation of several angiogenic, cell-migration, and proliferation-inducing factors including fibroblast growth factor 2, vascular endothelial growth factor (VEGF), urokinase-type plasminogen activator, and matrix metalloproteinase [5]. Peroxynitrite, the reaction product of superoxide and NO, is also an important mediator of hyperoxia-induced vaso-obliteration [6].
###end p 13
###begin p 14
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 96 100 96 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 155 159 155 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 190 194 190 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 241 242 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 355 356 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 411 412 411 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
The expression of eNOS is affected by functional polymorphisms of the eNOS gene. Particularly, T-786C in the promoter region and 27-bp repeat in intron 4 (eNOS b/a) with resultant decreased eNOS gene expression have gained more attention [7,8]. These polymorphisms have already been reported to be associated with diabetic retinopathy in type 1 diabetes [9,10] and also with numerous cardiovascular diseases [7,8].
###end p 14
###begin p 15
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 170 174 170 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 176 180 176 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 186 190 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 289 296 <span type="species:ncbi:9606">infants</span>
###xml 298 301 <span type="species:ncbi:9606">LBW</span>
In view of the key role of eNOS in vasculo- and angiogenesis and the association of eNOS polymorphisms with diabetic retinopathy, we investigated the association between eNOS T-786C and eNOS 27-bp repeat (b/a) functional polymorphisms and the development of severe ROP in low birth weight infants (LBW).
###end p 15
###begin title 16
Methods
###end title 16
###begin p 17
###xml 104 108 104 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 133 137 133 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
###xml 36 39 <span type="species:ncbi:9606">LBW</span>
###xml 411 418 <span type="species:ncbi:9606">infants</span>
###xml 717 725 <span type="species:ncbi:9606">children</span>
We monitored 232 patients born with LBW (less than or equal to 2000 g) between years 2000 and 2003 for T-786C and 27-bp repeat (b/a) eNOS gene polymorphisms. They were treated in the neonatal intensive care unit centers of Agost Schopf-Merei Institute of Obstetrics, the first Department of Gynecology and Obstetrics, and the second Department of Gynecology and Obstetrics, Semmelweis University, Budapest. All infants enrolled in the study were of Caucasian race. An independent university ethical committee approved our retrospective study (licence No: 16/2003). The research followed the tenets of the Declaration of Helsinki, and informed consent was obtained from the parents to collect blood samples from their children for diagnostic and scientific purposes.
###end p 17
###begin p 18
###xml 4 11 <span type="species:ncbi:9606">infants</span>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
###xml 302 309 <span type="species:ncbi:9606">infants</span>
All infants underwent ophthalmologic examination. Maximun ROP stage was assessed and therapy was decided after consultation with two out of the three available neonatal ophthalmologists. The patients were divided into two groups based on requirement for ROP treatment. The first group consisted of 105 infants who had been treated with laser or cryotherapy due to ROP stage 2+ or 5. The mean gestational age was 28+/-2.5 weeks and mean birth weight was 1150+/-360 g (treated group).
###end p 18
###begin p 19
###xml 38 41 <span type="species:ncbi:9606">LBW</span>
###xml 42 49 <span type="species:ncbi:9606">infants</span>
The second group enrolled 127 preterm LBW infants with ROP stage 1 or 2 who did not require cryotherapy/photocoagulation. The mean gestational age was 30.5+/-3.5 weeks and birth weight was 1300+/-400 g (untreated group).
###end p 19
###begin p 20
###xml 160 164 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 166 170 164 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 236 238 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 490 497 470 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 616 620 596 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 622 626 602 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 745 749 725 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 851 859 831 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
DNA for genotyping was extracted from filter papers with an extracting agent (Chelex(R); BioRad, Munich, Germany) according to the manufacturers' instructions. eNOS T-786C SNP was detected using a procedure described by Nasreen et al. [11]. A 27-bp repeat polymorphism was determined using allele-specific PCR with the following conditions: 30 s at 94 degreesC (denaturing), 60 s at 60 degreesC (annealing), and 30 s at 72 degreesC (extension) for 40 cycles. Primer pairs are summarized in Table 1. PCR products were separated on 2.5% agarose gels and visualized under ultraviolet illumination. By the genotyping of eNOS T-786C, the C and T alleles gave a 176 and 250-bp product, respectively, with a 387-bp common product. PCR amplification of eNOS 27-bp repeat polymorphism resulted in a product length of 407-bp (b allele) and of 380-bp (a allele, Figure 1).
###end p 20
###begin title 21
Primer pairs used for allele-specific polymerase chain reaction analysis.
###end title 21
###begin p 22
Artificially introduced mismatches in the primer sequences are noted in red.
###end p 22
###begin p 23
###xml 126 130 126 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 145 146 145 146 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 152 156 152 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 158 162 158 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 165 166 165 166 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
Two represetative pictures of eNOS genotyping. The two pictures show typical results of the allele-specific PCR reactions for eNOS 27-bp repeat (A) and eNOS T-786C (B) polymorphisms.
###end p 23
###begin p 24
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 69 73 69 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 299 300 299 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 425 429 425 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 644 646 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 665 667 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
The  software was used to assess Hardy-Weinberg equilibrium of eNOS T-786C and eNOS 27-bp repeat polymorphisms. The statistical difference, allele frequencies and haplotype distributions among the groups were compared using the chi-square test. Continuous clinical data were compared with Student's t-test. Logistic regression analysis was used to assess the association between the need for cryotherapy/photocoagulation and eNOS genotypes. The association was adjusted for proven risk factors of ROP [12]: gestational age, days on supplemental oxygen therapy, and their interaction. We perfomed our statistical calculations with the R system [13], using its MASS [14] package.
###end p 24
###begin title 25
Results
###end title 25
###begin p 26
###xml 189 193 189 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 195 199 195 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 205 209 205 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 31 34 <span type="species:ncbi:9606">LBW</span>
###xml 35 42 <span type="species:ncbi:9606">infants</span>
###xml 117 124 <span type="species:ncbi:9606">infants</span>
Our study enrolled 127 preterm LBW infants with stage 1 or stage 2 ROP who did not require treatment and 105 preterm infants whose ROP required therapy. We assessed their genotypes for the eNOS T-786C and eNOS 27-bp repeat polymorphisms.
###end p 26
###begin p 27
###xml 58 65 58 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
The clinical characteristics of the patients are shown in Table 2. Both assessed genotypes were in linkage disequilibrium and in Hardy-Weinberg equilibrium, irrespective of ROP treatment.
###end p 27
###begin title 28
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient clinical data.
###end title 28
###begin p 29
###xml 20 26 <span type="species:ncbi:9606">infant</span>
Gestational age and infant birth weight are shown as mean+/-SD. The mean and range are provided for days on, supplemental oxygen therapy. In the table, ROP represents retinopathy of prematurity.
###end p 29
###begin p 30
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 225 229 225 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 231 235 231 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 292 299 292 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
Analysis of genotype distributions revealed that the genotype distribution of eNOS 27-bp repeat polymorphism was significantly different in the treated group (p=0.015). There was no difference in the genotype distribution of eNOS T-786C polymorphism compared to the untreated group (p=0.984; Table 3).
###end p 30
###begin title 31
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 53 57 53 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 87 94 <span type="species:ncbi:9606">infants</span>
Genotype distribution of eNOS 27-bp repeat and eNOS T-786C polymorphisms two groups of infants with retinopathy of prematurity.
###end title 31
###begin p 32
###xml 7 8 7 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 95 102 <span type="species:ncbi:9606">infants</span>
###xml 199 206 <span type="species:ncbi:9606">infants</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
The chi2 test was used to compare genotype distribution of the different polymorphisms between infants with stage 1 or 2 retinopathy of prematurity (ROP) that was not severe enough to be treated and infants whose severe ROP required treatment. Data are given as the number of patients.
###end p 32
###begin p 33
###xml 105 109 105 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 131 135 131 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 135 139 135 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 200 207 200 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
A comparison of the allele frequencies revealed no significant difference in the allele distributions of eNOS 27-bp repeat "a" and eNOS-786C between the two groups (p=0.153 and p=0.867, respectively; Table 4).
###end p 33
###begin title 34
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 51 55 51 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 88 95 <span type="species:ncbi:9606">infants</span>
Allele distribution of eNOS 27-bp repeat and eNOS T-786C polymorphisms in two groups of infants with retinopathy of prematurity.
###end title 34
###begin p 35
###xml 7 8 7 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 87 94 <span type="species:ncbi:9606">infants</span>
###xml 164 171 <span type="species:ncbi:9606">infants</span>
The chi2 test was used to compare allele distribution of each polymorphism between the infants whose retinopathy of prematurity (ROP) did not require treatment and infants whose ROP was treated. The frequencies of alleles are given as percentages.
###end p 35
###begin p 36
###xml 226 230 226 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 280 287 280 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 303 307 303 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 418 425 <span type="species:ncbi:9606">infants</span>
Multiple logistic regression was performed to analyze the relevance of selected parameters (gender, gestational age, time on oxygen therapy and the interaction of gestational age and length of oxygen therapy, and genotypes of eNOS 27-bp repeat polymorphism). Results are shown in Table 5. We found that eNOS aa genotype and male gender were significant predictors of the onset of ROP requiring treatment among preterm infants (p=0.047 versus ab genotype and p=0.022 versus bb genotype and p=0.046 versus females).
###end p 36
###begin title 37
TResults of multiple regression analysis.
###end title 37
###begin p 38
###xml 169 173 169 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 145 152 <span type="species:ncbi:9606">infants</span>
Models were adjusted by logistic regression analysis for the association with retinopathy of prematurity (ROP) requiring treatment among preterm infants. Association of eNOS genotypes was adjusted for gender, gestational age and days of oxygen therapy and for the association of gestational age and days of oxygen therapy.
###end p 38
###begin p 39
###xml 135 139 135 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 291 298 291 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t6">Table 6</xref>
###xml 197 204 <span type="species:ncbi:9606">infants</span>
Based on the genotype distributions, we estimated and compared four haplotypes between the treated and untreated groups. We found that eNOS aT and bT haplotypes were significantly increased in the infants treated for ROP compared to the untreated group (p=0.0001 and p=0.0036, respectively; Table 6).
###end p 39
###begin title 40
Results of the haplotype analysis.
###end title 40
###begin p 41
###xml 58 65 <span type="species:ncbi:9606">infants</span>
###xml 135 142 <span type="species:ncbi:9606">infants</span>
Data are given as percentages. The comparison was made in infants whose retinopathy of prematurity (ROP) did not require treatment and infants whose ROP was treated.
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 95 96 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 252 253 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 311 315 311 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 317 321 317 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 359 360 359 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 463 467 463 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 469 473 469 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 532 536 532 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 631 633 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
Several studies have investigated the role of eNOS in connection with ophthalmologic diseases [9,10,15-20]. Different eNOS polymorphisms in association with diabetic retinopathy (DR) have been studied extensively. The data are, however, controversial [9,10,18-20]. De Syllos et al. found no association between eNOS T-786C and Glu298Asp polymorphisms and DR [9]. These results were confirmed by Awata et al. [18]. Yet, a study by Taverna et al. demonstrated that eNOS T-786C did indeed affect the onset pattern of DR [19]. However, eNOS 27-bp repeat polymorphism was not found to be associated with DR in either of the studies [18,20].
###end p 43
###begin p 44
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 73 77 73 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 181 185 181 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 365 369 365 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
This is the first study to investigate the relevance of functional eNOS T-786C and 27-bp repeat polymorphisms in the pathogenesis of ROP. We found that the genotype distribution of eNOS 27-bp repeat was significantly different between the study groups; however there was no difference in the frequency of the "a" allele. Using multiple logistic regression analysis eNOS aa genotype was proved to be associated with the onset of ROP requiring treatment. The association was adjusted for ROP risk factors such as gender, gestational age and time on oxygen therapy and for the interaction of gestational age and time on oxygen therapy. We found a significant difference in the birth weight between the two study groups as well, but because there was a strong correlation between the gestational age and birth weight (0.9), we made no adjustment for birth weight.
###end p 44
###begin p 45
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 74 78 74 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 117 121 117 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
There was no significant difference in the genotype distribution of eNOS T-786C polymorphism nor in the frequency of -786C allele between the treated and untreated groups.
###end p 45
###begin p 46
Haplotype estimations revealed that prevalence of aT and bT haplotypes was significantly higher in the treated group.
###end p 46
###begin p 47
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
During the first phase of ROP, exposure of the developing retina to relative hyperoxia results in vaso-obliteration in which peroxynitrite, the reaction product of superoxide and NO, has a central role [16].
###end p 47
###begin p 48
###xml 156 160 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 171 176 <span type="species:ncbi:10090">mouse</span>
###xml 386 389 <span type="species:ncbi:10116">rat</span>
Brooks et al. showed that oxygen-induced vaso-obliteration in the retina was reduced by administration of an NOS inhibitor or by targeted disruption of the eNOS gene in a mouse model, indicating a deleterious role of eNOS-derived NO in the first phase of ROP [15]. Beauchamp et al. found that inhibition of NOS aggravated the retinal vaso-obliteration during exposure to hyperoxia in a rat model [16].
###end p 48
###begin p 49
The vaso-obliterative first phase of ROP leads to retinal hypoxia, which, in turn, predisposes to the second phase characterized by abnormal vasoproliferation. Evidence suggests that NO can inhibit angiogenesis under some circumstances, however, present data are controversial.
###end p 49
###begin p 50
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 162 166 162 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 18 23 <span type="species:ncbi:9031">chick</span>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
Mouse implant and chick chorioallantoic membrane models can be used to inhibit, angiogenesis by a NO-donor S-nitroso N-acetyl glutathione [21]. Ando, et al. used eNOS knockout mice with ischemic retinopathy and detected, a significant decrease in neovascularization [17]. Interestingly, Campochiaro et al. found that NO in low concentrations triggered the expression of VEGF, which then induced neoangiogenesis [22].
###end p 50
###begin p 51
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
Functional 27-bp repeat polymorphism has a significant role in eNOS production. Tsukada et al. and Hoffmann et al. showed a strong association between eNOS 27-bp repeat polymorphism and plasma NO metabolite levels in healthy subjects [23,24]. Li et al. also reported that NO metabolite levels were lower in those who carry the "a" allele [25]. Indeed, it was demonstrated that nuclear proteins could bind to the 27-bp repeat sequence and therefore decrease gene transcription.
###end p 51
###begin p 52
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 216 220 216 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 397 401 397 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
Decreased NO production may aggravate retinal vaso-obliteration during the first phase of ROP [15] and then the neoangiogenesis in the second phase [22]. This could explain the association found in our study between eNOS 27-bp aa genotype, leading to decreased eNOS production and severe ROP. However, the serum levels of NO should be determined in order to find out the exact association between eNOS 27-bp repeat polymorphism and the risk and severity of ROP.
###end p 52
###begin p 53
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 463 467 463 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
It is also conceivable that the observed association between 27-bp repeat polymorphism and the severity of ROP is not directly related to NO production capacity. The eNOS gene is located near other genes, e.g., T-cell antigen receptor constant beta-chain, which has been shown to be strongly associated with susceptibility to microvascular complications such as retinopathy in type 1 diabetes [26]. Therefore, it is possible that the observed association between eNOS 27-bp repeat polymorphism and the severity of ROP is the result of linkage disequilibrium with other gene mutations.
###end p 53
###begin p 54
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 285 289 285 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 416 420 416 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 422 426 422 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;786</sup>
###xml 478 482 478 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 131 138 <span type="species:ncbi:9606">infants</span>
###xml 196 203 <span type="species:ncbi:9606">infants</span>
###xml 204 211 <span type="species:ncbi:9606">infants</span>
###xml 620 627 <span type="species:ncbi:9606">patient</span>
In conclusion, we observed that the genotype distribution of eNOS 27-bp repeat polymorphism was significantly different in preterm infants treated for severe proliferating ROP compared to preterm infants infants with stage 1 or 2 ROP that did not require treatment. We also found that eNOS 27-bp aa genotype presented an independent risk factor for ROP requiring treatment. On the other hand, no association between eNOS T-786C and ROP was observed. These findings suggest that eNOS 27-bp repeat polymorphism might be associated with the development of proliferative ROP and a indicate the importance of determining the patient's genetic background when planning individual therapy.
###end p 54
###begin title 55
Acknowledgments
###end title 55
###begin p 56
###xml 252 259 <span type="species:ncbi:9606">infants</span>
The authors thank Andras Treszl, Ph.D. and Gyorgy Duna, M.D. for collecting blood samples and clinical data and Rita Vamos, M.D. from the Clinic of Ophtalmology, Maria Street, Semmelweis University, Budapest for conducting physical examinations of the infants. This study was supported by grants from OTKA F042563-F048842 and ETT 184/2003. A. F., B. V. and A. J. S. are recipients of the Bolyai scholarship.
###end p 56
###begin title 57
References
###end title 57
###begin article-title 58
Pathogenesis of retinopathy of prematurity.
###end article-title 58
###begin article-title 59
Nitric oxide: pathophysiological mechanisms.
###end article-title 59
###begin article-title 60
Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis.
###end article-title 60
###begin article-title 61
Nitric oxide and angiogenesis.
###end article-title 61
###begin article-title 62
Hyperoxia induces retinal vascular endothelial cell apoptosis through formation of peroxynitrite.
###end article-title 62
###begin article-title 63
Endothelial nitric oxide synthase gene is positively associated with essential hypertension.
###end article-title 63
###begin article-title 64
T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm.
###end article-title 64
###begin article-title 65
###xml 121 129 <span type="species:ncbi:9606">patients</span>
Endothelial nitric oxide synthase genotype and haplotype are not associated with diabetic retinopathy in diabetes type 2 patients.
###end article-title 65
###begin article-title 66
eNOS4 polymorphism of the endothelial nitric oxide synthase predicts risk for severe diabetic retinopathy.
###end article-title 66
###begin article-title 67
T-786C polymorphism in endothelial NO synthase gene affects cerebral circulation in smokers: possible gene-environmental interaction.
###end article-title 67
###begin article-title 68
Current incidence of retinopathy of prematurity, 1989-1997.
###end article-title 68
###begin article-title 69
###xml 65 69 <span type="species:ncbi:10090">mice</span>
Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice.
###end article-title 69
###begin article-title 70
Redox-dependent effects of nitric oxide on microvascular integrity in oxygen-induced retinopathy.
###end article-title 70
###begin article-title 71
Nitric oxide is proangiogenic in the retina and choroid.
###end article-title 71
###begin article-title 72
Endothelial nitric oxide synthase gene is associated with diabetic macular edema in type 2 diabetes.
###end article-title 72
###begin article-title 73
The T-786C and C774T endothelial nitric oxide synthase gene polymorphisms independently affect the onset pattern of severe diabetic retinopathy.
###end article-title 73
###begin article-title 74
Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy.
###end article-title 74
###begin article-title 75
Antiangiogenesis efficacy of nitric oxide donors.
###end article-title 75
###begin article-title 76
Retinal and choroidal neovascularization.
###end article-title 76
###begin article-title 77
###xml 91 97 <span type="species:ncbi:9606">humans</span>
Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans.
###end article-title 77
###begin article-title 78
Endothelial nitric oxide synthase polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in Hispanics.
###end article-title 78
###begin article-title 79
Relation of endothelial nitric oxide synthase gene to plasma nitric oxide level, endothelial function, and blood pressure in African Americans.
###end article-title 79
###begin article-title 80
T-cell receptor constant beta chain polymorphisms and susceptibility to type 1 diabetes.
###end article-title 80

